ArticleNeurochemical research2026
Decorin Attenuates Epileptogenesis and Modulates Hippocampal Synaptic Plasticity via the mTOR Signalling Pathway.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The pathophysiological mechanism of epilepsy has not been fully elucidated. Abnormal synaptic plasticity in the hippocampus may be an important trigger. Decorin (DCN), an extracellular matrix protein, may affect synaptic remodeling by regulating the mTOR signalling pathway. However, its role and molecular mechanism in epilepsy remain unclear. In this study, a chronic epilepsy mouse model induced by kainic acid (KA) was established. The protein expression of DCN in the hippocampus was significantly increased during the occurrence of epilepsy. By using an adeno-associated virus (AAV) to knock down DCN expression in the hippocampus, the effect of DCN on the occurrence of epilepsy was explored. The experiments revealed that knocking down DCN could significantly shorten the duration of status epilepticus, reduce the frequency and severity of spontaneous seizures, etc. Moreover, DCN knockdown could improve synaptic remodelling by downregulating the expression of key proteins, such as AMPA/NMDA receptor subunits (GluN2A, GluN2B) and PSD95, on the postsynaptic membrane, and reducing the abnormal increase in dendritic spine density and the number of synaptic vesicles. Molecular mechanism studies revealed that DCN physically interacts with mTOR protein, and its knockdown coincided with reduced phosphorylation and activation of mTOR. These findings suggest a potential link between DCN and mTOR signalling. Therefore, the DCN-mTOR axis emerges as a potential target for modulating the excessive synaptic transmission associated with epilepsy. This study is the first to reveal that DCN participates in the pathological process of epilepsy by regulating mTOR-dependent synaptic plasticity, providing experimental evidence that the DCN-mTOR axis can be targeted to intervene in synaptic homeostasis imbalance.
Indexed as
Identifiers
41701388What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.